Document is current
Any future updates will be listed below
-
Authors
Kulkarni, Sanjana G. https://orcid.org/0000-0002-9883-610X
Laurent, Sacha
Miotto, Paolo https://orcid.org/0000-0003-4610-2427
Walker, Timothy M.
Chindelevitch, Leonid
Nathanson, Carl-Michael
Ismail, Nazir https://orcid.org/0000-0001-7696-3776
Rodwell, Timothy C.
Farhat, Maha R. https://orcid.org/0000-0002-3871-5760
-
Funding
Funding for this research was provided by:
National Science Foundation (DGE 2140743)
U.S. Department of Health & Human Services | National Institutes of Health (R01AI155765)
- License Information
-
More Information
Article History
Received: 5 July 2024
Accepted: 11 February 2025
First Online: 4 March 2025
Competing interests
: T.C.R. received funding support from FIND through a service contract with UC San Diego. T.C.R. received grant funding from NIH to develop and evaluate a tNGS solution for drug resistant TB (R01AI176401). T.C.R. is a co-founder, board member and unpaid shareholder of Verus Diagnostics Inc. T.C.R. is a co-inventor on patents pertaining to tNGS. The remaining authors declare no competing interests.
